Barriers to vaccination service delivery within general practice: opportunity to make a sustainable difference in Aboriginal child health?
CONCLUSION: Inadequate awareness of the current rates, in association with a lack of cultural safety training, follow-up and opportunistic practice, may be preventing greater vaccination uptake in Aboriginal children in Perth. Cultural safety is a critical component of the acceptability and accessibility of services; lack of awareness may restrict the development of strategies designed to equitably address low coverage. IMPLICATIONS: The findings of this study provide an opportunity to raise awareness among clinicians in general practice and inform future strategies to equitably deliver targeted vaccination services to Aboriginal children. PMID: 31535420 [PubMed - as supplied by publisher]
Lab Chip, 2020, Accepted Manuscript DOI: 10.1039/C9LC01165J, PaperJose Wippold, Han Wang, Joseph Tingling, Julian Leibowitz, Paul de Figueiredo, Arum Han Identifying antibodies (Abs) that neutralize infectious agents is the first step for developing therapeutics, vaccines, and diagnostic tools for those infectious agents. However, current approaches for identifying neutralizing Abs (nAbs)... The content of this RSS Feed (c) The Royal Society of Chemistry
Researchers at the US National Institutes of Health tested an experimental antiviral drug, first created for Ebola, on 18 rhesus macaques.
Funding Opportunity RFA-AI-20-019 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support novel strategies for the rational design of vaccines against hepatitis C virus (HCV), to assess the vaccines for their ability to induce protective immune responses, and to select candidates for preclinical development and clinical testing. To this end, it will be critical to advance knowledge of the structural basis for broad immunological protection, and to elucidate correlates of HCV protection by leveraging samples from existing human cohorts and vaccine studies. This ...
CORONAVIRUS is continuing to spread around the globe, with outbreaks worsening in Italy and South Korea. But is there a cure - does a vaccine exist? And if so, who will will be the first to get it?
(Harvard Medical School) Harvard University scientists will collaborate with Chinese colleagues to tackle the most pressing challenges posed by the novel coronavirus (COVID-19) disease. Their efforts are aimed at elucidating the basic biology of the virus, and the resulting disease, toward new diagnostic tools, vaccine development and antiviral therapies. The collaboration is part of a $115 million, 5-year research initiative funded by China Evergrande Group.
ConclusionsThough the number of pro-vaccine posts increased, antivaccine posts remained more popular. The government agency may use an emotive personal family-oriented message to promote vaccination.
"We are excited with the launch of the quadrivalent version of our flu vaccine, which can be offered to both children above six months and adults. This particular type of vaccine provides good immune response with less side-effects," Abbott India Medical Director Srirupa Das said.
AbstractPurpose of ReviewWe reviewed the benefit of influenza vaccination in healthcare personnel (HCP), rates of vaccine coverage, and practices used to try to boost vaccine coverage among HCP.Recent FindingsInfluenza vaccination in HCP provides benefits to both HCP and patients, including reductions in patient morbidity and mortality and decreases in HCP absenteeism. Despite these benefits, influenza vaccine coverage among HCP still falls short of the Healthy People 2020 goal of 90%. As a result, healthcare institutions have used various practices to boost vaccination, including mandatory vaccine policies and requiring n...
by Fatima Laher, Zoe Moodie, Kristen W. Cohen, Nicole Grunenberg, Linda-Gail Bekker, Mary Allen, Nicole Frahm, Nicole L. Yates, Lynn Morris, Mookho Malahleha, Kathryn Mngadi, Brodie Daniels, Craig Innes, Kevin Saunders, Shannon Grant, Chenchen Yu, Peter B. Gilbert, Sanjay Phogat, Carlos A. DiazGranados, Marguerite Koutsoukos, Olivier Van Der Meeren, Carter Bentley, Nonhlanhla N. Mkhize, Michael N. Pensiero, Vijay L. Mehra, James G. Kublin, Lawrence Corey, David C. Montefiori, Glenda E. Gray, M. Juliana McElrath, Georgia D. Tomaras BackgroundHVTN 100 evaluated the safety and immunogenicity of an HIV subtype C pox-protein va...